1 completed, 1 terminated, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow Stage IIB Rectal Cancer: new trials by email Literature Review of Stage IIB Rectal Cancer trials Research Report on Stage IIB Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment Laboratory Biomarker Analysis, Regorafenib - Rectal Adenocarcinoma, Stage IIA Rectal Cancer | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2015-03-01 | 2016-10-12 | |
| Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer bevacizumab, oxaliplatin, leucovorin calcium - Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum | Phase 2 | Terminated | University of Southern California | 17 | 2013-08-02 | 2026-07-01 |
| Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma erlotinib hydrochloride, placebo, laboratory biomarker analysis - Adenomatous Polyp, Recurrent Colon Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2008-07-01 | 2015-01-06 |
Rectal Neoplasms (3) · Adenomatous Polyps (1) · Colonic Neoplasms (1)
Colorectal Neoplasms (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Rectal Diseases (3) · Adenoma (1) · Colonic Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
Bevacizumab (1) · Erlotinib Hydrochloride (1) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · regorafenib (1)
National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (3)
Afsaneh Barzi (1) · Patrick Boland (1) · Timothy Morgan (1)
N01CN35160 (1), P30CA014089 (1), P30CA016056 (1)